HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Appropriations Subcommittee Proposes FDA FY2024 Budget $662M Short Of Request

Executive Summary

Appropriations Agriculture, Rural Development, FDA and Related Agencies Subcommittee marked up its FY2024 bill on 18 May, proposing $6.579bn for FDA. Total is up from current budget of $6.562bn, but Biden administration proposed $7.2bn for FY2024.

You may also be interested in...



OTC Drugs, Dietary Supplements Merit Scant Mention In $7.2Bn FDA FY2024 Budget Request

Supplements and OTC drug categories each mentioned once in FY2024 budget request for agency published by HHS. Broader document provided by White House OMB makes no mention of either category while emphasizing proposed increase for FDA’s food programs.

Congress Boosts FDA Food Safety Budget Nearly $700M, Orders Reports On Formula Supply

Appropriators are “concerned by the fragility of the infant formula supply chain and the detrimental health impacts that can arise from shortage of these regulated products.” Their report published with FY2023 omnibus appropriations also asks for list of Russian firms with pending NDAs, including OTCs.

Homeopathics, Supplements, OTC Medicines Overlap In Pharmacists’ ‘Over-The-Counter’ Survey

Results of U.S. News & World Report’s first “Best OTC Medicine & Health Products” survey include homeopathic formulations, supplements and non-drug topicals in same categories of indications with nonprescription pharmaceuticals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel